-
<![CDATA[Hernexeos Effective in HER2-Mutated NSCLC]]>
26 Oct 2025 17:00 GMT
… with untreated, advanced HER2-mutated non-small cell lung cancer (NSCLC), treatment with Hernexeos (zongertinib) … patients with advanced HER2-mutant NSCLC,” Sanjay Popat, consultant medical … metastatic or unresectable non-squamous NSCLC who had HER2 TKD …
-
The Value of Dynamic of Alkaline Phosphatase and Neutrophil-to-Lymphocyte Ratio in Predicting the Efficacy of Neoadjuvant Immunochemotherapy in Patients with Non-Small Cell Lung Cancer
25 Oct 2025 08:42 GMT
… following neoadjuvant immunochemotherapy in NSCLC patients. Univariate and … Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): updated Outcomes from … Pathological Response for Resectable Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy …
-
<![CDATA[Chemotherapy Combination Boosts Overall Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer]]>
24 Oct 2025 22:54 GMT
… newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone. … patients in Asia with NSCLC harbor epidermal growth factor … newly diagnosed EGFR-mutant non-small cell lung cancer, including combination therapies and …
-
SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
23 Oct 2025 20:03 GMT
TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central …
-
MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
23 Oct 2025 12:36 GMT
… trials of ateganosine in non-small cell lung cancer (NSCLC). “The posters showcased … in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Resistant to Prior ICI … evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with …
-
N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
23 Oct 2025 12:25 GMT
Neve Yarak, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced today the closing of the merger …
-
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
22 Oct 2025 16:12 GMT
… treated patients with KRAS G12C non-small cell lung cancer (NSCLC) who had received a prior … . About Non-Small Cell Lung Cancer
More than 197,000 people are diagnosed with non-small cell lung cancer (NSCLC) in …
-
<![CDATA[Sunvozertinib Proves Efficacy in EGFR-Mutant Non-Small Cell Lung Cancer ]]>
21 Oct 2025 23:13 GMT
… cell lung cancer (NSCLC) with epidermal growth … treatment of EGFR exon20ins NSCLC,” stated the authors … treatment-naive advanced EGFR exon20ins NSCLC.
REFERENCES:
1. Yang … Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28). ClinicalTrials. …
-
<![CDATA[Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum]]>
24 Oct 2025 22:54 GMT
… driven treatment for EGFR-mutant non-small cell lung cancer.
Learning Objectives
Upon successful … line treatment of EGFR-mutated NSCLC
Formulate appropriate strategies for … to EGFR targeted therapies in NSCLC
·Develop individualized treatment plans …
-
<![CDATA[ROS1-Targeting Therapies Show “Suboptimal” Efficacy in ROS1-Mutated NSCLC]]>
24 Oct 2025 22:41 GMT
… care for ROS1-positive advanced NSCLC (n = 103), the … adult patients with advanced NSCLC, defined as those with … Patients diagnosed with advanced NSCLC between 2009 and 2023 … advanced or metastatic (LAM) non-small cell lung cancer (NSCLC) in Canada and Europe. …
About
© 1995-2025